 | | Vol. 16.13 – 4 April, 2024 |
| |
|
|
| The authors investigated genetic and transcriptional changes underlying tumor awakening, and it was demonstrated that endocrine therapies induced nongenetic cell state transitions into dormancy in a stochastic subset of cells via epigenetic reprogramming.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The effects of ropivacaine on breast cancer stemness were investigated by in vitro and in vivo assays. Scientists reported that ropivacaine suppressed stem cell-like properties of breast cancer cells.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Investigators demonstrated a vesicular-trafficking-mediated interplay between matriptase and epidermal growth factor (EGF) signaling in skin and breast cancer promotion. EGF induced matriptase to undergo endocytosis together with the EGF receptor, followed by acid-induced activation in endosomes.
[Cell Reports] |
|
|
|
| Scientists observed that β1-integrin was required for human prostate and breast cancer cell adhesion to endothelial cells (EC) under shear-stress conditions in vitro and to lung blood vessel ECs in vivo.
[Cell Reports] |
|
|
|
| The authors established 75 patient-derived breast cancer organoid models. The results of H&E staining, immunohistochemical, and whole-exome sequencing revealed that patient-derived organoids inherited the histologic and genetic characteristics of their parental tumor tissues.
[International Journal Of Cancer] |
|
|
|
| Researchers explored the biological function of mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) in radioresistant breast cancer cells using two MAP4K4 inhibitors.
[Scientific Reports] |
|
|
|
| To test whether Mbd2 played a causal role in mammary tumor growth and metastasis, the authors performed genetic knockout (KO) of Mbd2 in transgenic mice and compared mammary tumor progression kinetics between the wild-type and KO groups.
[Experimental And Molecular Pathology] |
|
|
|
|
| The authors review the key signaling pathways in breast cancer that may contribute to ductal carcinoma in situ (DCIS) initiation and progression. They also explore the molecular features of DCIS and invasive ductal carcinoma.
[Signal Transduction And Targeted Therapy] |
|
|
|
|
| AstraZeneca and Daiichi Sankyo’s Biologics License Application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.
[AstraZeneca] |
|
|
|
|
|
|
|
| | Ohio State University – Columbus, Ohio, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
